.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Moodys
Federal Trade Commission
UBS
Daiichi Sankyo
Harvard Business School
Covington
Cipla
Accenture
Colorcon

Generated: November 21, 2017

DrugPatentWatch Database Preview

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER Drug Profile

« Back to Dashboard

What is the patent landscape for Brevibloc Double Strength In Plastic Container, and what generic Brevibloc Double Strength In Plastic Container alternatives are available?

Brevibloc Double Strength In Plastic Container is a drug marketed by Baxter Hlthcare and is included in one NDA. There are two patents protecting this drug.

This drug has thirty-six patent family members in twenty-four countries.

The generic ingredient in BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER is esmolol hydrochloride. There are eight drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the esmolol hydrochloride profile page.

Pharmacology for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER
esmolol hydrochloride
INJECTABLE;INJECTION019386-005Jan 27, 2003RXYesYes► Subscribe► SubscribeY► Subscribe
Baxter Hlthcare
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER
esmolol hydrochloride
INJECTABLE;INJECTION019386-005Jan 27, 2003RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Baxter Hlthcare
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER
esmolol hydrochloride
INJECTABLE;INJECTION019386-005Jan 27, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

Country Document Number Estimated Expiration
European Patent Office1738756► Subscribe
Turkey200202557► Subscribe
Czech Republic304290► Subscribe
Australia2002309475► Subscribe
Poland216192► Subscribe
Slovakia12782002► Subscribe
Czech Republic20023825► Subscribe
Poland357387► Subscribe
Hungary0204520► Subscribe
Russian Federation2002132189► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Argus Health
Covington
Moodys
Johnson and Johnson
Teva
Fuji
Colorcon
Mallinckrodt
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot